Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomarkers, Communications Are Key To Accelerating R&D, FDA Says

Executive Summary

Genentech's Herceptin is a good example of how the tradeoffs in targeted drug development can work out medically and commercially, FDA Commissioner McClellan told an IBC meeting in Boston Aug. 12

You may also be interested in...



Abbott Rx For R&D Includes Tandem Drug/Biologic Development

Developing biologics and drugs in tandem for the same target is one method Abbott is using to improve R&D productivity

Abbott Rx For R&D Includes Tandem Drug/Biologic Development

Developing biologics and drugs in tandem for the same target is one method Abbott is using to improve R&D productivity

FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought

FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31

UsernamePublicRestriction

Register

PS045148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel